Oramed Pharmaceuticals Inc
Research Oramed Pharmaceuticals Inc (ORMP) on Bullrun: market cap USD 176.41M, P/E 1.0, dividend yield 5.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerORMP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 176.41M
- P/E1.0
- Dividend yield5.9%
- Financial periodQ2 2026
- RevenueUSD 0
- Net incomeUSD 78.16M
- Free cash flow-USD 202.00K
Valuation Snapshot
latest market cap is USD 176.41M; P/E is 1.0; dividend yield is 5.9%.
Peer valuation comparison
Latest P/E is 1.04x versus a Healthcare sector median of 24.6x (95.8% below).
Latest dividend yield is 5.85% versus a Healthcare sector median of 1.84% (217.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.00M | USD 64.05M | -USD 9.15M | 0.7% | 1.5 | USD 45.95M | USD 825.00K | USD 199.74M |
| FY2024 | USD 0 | -USD 19.06M | -USD 8.43M | n/a | -0.48 | USD 54.42M | USD 372.00K | USD 146.27M |
| FY2023 | USD 1.34M | USD 5.09M | -USD 10.55M | n/a | 0.14 | USD 9.06M | USD 51.01M | USD 163.82M |
| FY2022 | USD 2.70M | -USD 36.56M | -USD 28.41M | n/a | -0.94 | USD 40.46M | USD 25.00K | USD 151.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 176.41M | 1.0 | 5.9% | 0.25 |
| 2025 | 2025-12-31 | USD 111.93M | 1.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 96.61M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 93.18M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 470.55M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 544.91M | n/a | n/a | n/a |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.25 USD, yield 5.9%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.25 USD |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Oramed Pharmaceuticals Inc's market cap?
Oramed Pharmaceuticals Inc's market capitalization is USD 176.41M.
What is Oramed Pharmaceuticals Inc's P/E ratio?
Oramed Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 1.0.
Does Oramed Pharmaceuticals Inc pay a dividend?
Oramed Pharmaceuticals Inc has a dividend yield of 5.9%.
What does Oramed Pharmaceuticals Inc do?
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.